ARTICLE | Clinical News
Prezista darunavir regulatory update
June 4, 2012 7:00 AM UTC
FDA issued a complete response letter for an sNDA from Johnson & Johnson's Janssen Therapeutics division for a single 800 mg daily tablet of HIV drug Prezista darunavir. Janssen said it is evaluating ...